Treatment of IgA1 deposition diseases

Details Treatment of IgA1 deposition diseases Treatment of IgA1 deposition diseases

2004-08-19

2008-08-05

Swope, Sheridan (Department: 1652)

Drug, bio-affecting and body treating compositions

Enzyme or coenzyme containing

Hydrolases

C435S212000

Reexamination Certificate

active

07407653

ABSTRACT:
The present invention discloses the use of bacterial IgA1 proteases to treat IgA1 deposition in tissue and organs. Bacterial IgA1 proteases specifically cleave IgA1 molecules and thus provide a means to specifically cleave and remove IgA1 depositions. Accordingly, therapeutic agents for the treatment of diseases characterized by IgA deposition are provided. In particular, therapeutic agents to treat IgA nephropathy, Dermatitis herpetiformis (DH), and Henoch-Schoenlein purpura (HS) are disclosed.

REFERENCES:
Galye et al, Identification of regions in interleukin-1 alpha important for activity. J Biol Chem. Oct. 15, 1993;268(29):22105-11.
Whisstock et al, Prediction of protein function from protein sequence and structure. Q Rev Biophys. Aug. 2003;36(3):307-40. Review.
Gesualdo et al, Enzymolysis of glomerular immune deposits in vivo with dextranase/protease ameliorates proteinuria, hematuria, and mesangial proliferation in murine experimental IgA nephropathy. J Clin Invest. Sep. 1990;86(3):715-22.
Hsu et al, The molecular pathogenesis and experimental therapy of IgA nephropathy: recent advances and future directions. Curr Mol Med. May 2001;1(2):183-96. Review.
Launay et al, Fcalpha receptor (CD89) mediates the development of immunoglobulin A (IgA) nephropathy (Berger's disease). Evidence for pathogenic soluble receptor-Iga complexes in patients and CD89 transgenic mice. J Exp Med. Jun. 5, 2000;191(11):1999-2009.
Restoker et al, High-dose immunoglobulin therapy for severe IgA nephropathy and Henoch-Schonlein purpura. Ann Intern Med. Mar. 15, 1994;120(6):476-84.
Appel et al, The IgA nephropathy treatment dilemma. Kidney Int. Jun. 2006;69(11):1939-44. Review.
Ballardie, IgA nephropathy treatment 25 years on: can we halt progression? The evidence base. Nephrol Dial Transplant. May 2004;19(5):1041-6. Review. No abstract available.
Coppo et al, Aberrant glycosylation in IgA nephropathy (IgAN). Kidney Int. May 2004;65(5):1544-7. Review.
Definition: “focal glomenulonephritis” In: Stedman's medical dictionary Ed 26 1995, pp. 727.
Kilian et al, IgA1 proteases fromHaemophilus influenzae, Streptococcus pneumoniae, Neisseria meningitidis, andStreptococcus sanguis: comparative immunochemical studies. J Immunol. Jun. 1980;124(6):2596-600.
Grundy et al, Localization of the cleavage site specificity determinant ofHaemophilus influenzaeimmunoglobulin A1 protease genes. Infect Immun. Feb. 1990;58(2):320-31.
Kilian et al, Pathogenic species of the genusHaemophilusandStreptococcus pneumoniaeproduce immunoglobulin A1 protease. Infect Immun. Oct. 1979;26(1):143-9.
Halter et al, IgA protease ofNeisseria gonorrhoeae: isolation and characterization of the gene and its extracellular product EMBO J. Jul. 1984;3(7):1595-601.
Kobayashi et al, IgA protease fromClostridium ramosumthat cleaves IgA1 and IgA2, A2m(1): the site of cleavage and digestion of secretory IgA. Adv Exp Med Biol. 1987;216B:1289-96.
Piesecki et al, Immobilization of -galactosidase for application in organic chemistry using a chelating peptide. Biotech & Bioeng. Jun. 1993; 42(2): 178-184.
Koshland et al, Selective proteolysis of the J chain component in human polymeric immunoglobulin. J Immunol. Mar. 1977;118(3):775-81.
Michael et al, Recurrent haematuria: role of renal biopsy and investigative morbidity. Br Med J. Mar. 20, 1976;1(6011):686-8.
Nakazawa, et al.; “Proteolytic Enzyme Treatment Reduces Glomerular Immune Deposits and Proteinuria in Passive Heymann Nephritis”; J. Exp. Med.; (1986); 164: 1973-1987.
Gesualdo, et al.; “Enzymolysis of Glomerular Immune Deposits In Vivo with Dextranase/Protease Ameliorates Proteinuria, Hematuria, and Mesangial Proliferation in Murine Experimental IgA Nephropathy”;J. Clin. Invest.; (1990); 86: 715-722.
Strauss, et al.; “C-terminal glycine-histidine tagging of the outer membrane protein Iga β ofNeisseria gonorrhoeae”; 1995;FEMS Microbiology Letters;127: 249-254.
International Search Report for International Application No. PCT/US04/06615 dated Aug. 16, 2005.
Smith, A. C., et al. “New insights into the pathogenesis of IgA nephropathy”, Springer Semin Immunopathol, pp. 477-493 (2003).
Barratt, et al., J. Am. Soc. Nephrol., 16:2088-2097, 2005.
Barratt, et al., Semin. Immunopathol., 29:427-443, 2007.
Julian, et al., Curr. Opin. Nephrol. Hypertens., 13: 171-179, 2004.

Affiliated with

Also associated with

Rating

Treatment of IgA1 deposition diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of IgA1 deposition diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of IgA1 deposition diseases will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4003481